摘要
目的探索低分子肝素联合贝那普利治疗糖尿病肾病蛋白尿的有效性和安全性。方法 62例糖尿病肾病患者随机分成两组。对照组给予一般常规治疗;治疗组在常规治疗基础上给予低分子肝素钙6000 U,1次/d,皮下注射,共2周;同时联合贝那普利10 mg,1次/d。两组患者均治疗4周。结果治疗组尿蛋白下降明显优于对照组(P<0.05)。两组血脂、肾功能、FIB、PT、APTT比较差异均无统计学意义(P>0.05)。结论低分子肝素联合贝那普利治疗可明显降低糖尿病肾病尿蛋白,延缓肾功能不全的发生,且无出血倾向。
Objective To probe into the effectiveness and safety of low - molecular - weight heparin with benazepril on Proteinuria in patient with Diabetic nephropathy. Methods 62cases with Diabetic nephropathy were randomly divided into two groups. The original scheme for treatment of patients in two groups was unchanged, including the decreasing blood glucose drug or insulin,the patients in the treated group were given Low - molecular - weight heparins calcium injection （ 6000 U once, hypodermic injection, one a day of 14 days ） and benazepril（ 10 mg once, one a day for 4 weeks）. 4 weeks as a therapy course in both 2 groups. Results A deerease in preteinuria were observed in the treated group, and was significantly superior to contrast group （ P 〈 0.05 ）. Changes of Hemolipids ,renal function FIB, PT and APTT of patients in two groups were not sig- nificant（P 〉 0.05）. Conclusion low- molecular- weight heparin with benazepril can decrease the proteinuria, and postpone renal unfunction in patients with Diabetic nephropathy ,without the side -effect of hemorrhage.
出处
《中国医学创新》
CAS
2011年第5期41-43,共3页
Medical Innovation of China
关键词
低分子肝素
贝那普利
糖尿病肾病
蛋白尿
Low - molecular - weight heparin
Benazepril
Diabetic nephropathy
Proteinuria
